Source:http://linkedlifedata.com/resource/pubmed/id/19323951
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2009-3-27
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:status |
PubMed-not-MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1539-0829
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
95-7
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
The dawn of prospective pharmacogenetic testing in type 2 diabetes.
|
| pubmed:affiliation |
Center for Human Genetic Research/Diabetes Unit, Massachusetts General Hospital, Boston, MA 02114, USA. jcfl orez@partners.org
|
| pubmed:publicationType |
Journal Article,
Comment
|